| About the author: |
N.A Zolotarova, O.V. Solomko |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
The side effects of the combination of statins and fibrates in patients with stable angina and low-mineralized silicon hydrocarbonate calcium-magnesium mineral water in their correction were studied. 64 patients were examined, divided into 2 groups. The first group received atorvastatin (10 mg) and fenofibrate (145 mg), the second group received low-mineralized silicon hydrocarbonate calcium-magnesium mineral water. It was found that use of atorvastatin and fenofibrate does not cause serious side effects, but undesirable effects, levels of alanine aminotransferase and creatine phosphokinase, increase. The positive effect of low-mineralized mineral water on clinical (prevention of symptoms from the digestive and hepatobiliary systems) and biochemical parameters were shown. Levels of creatine phosphokinase, alanine aminotransferase and aspartate aminotransferase decreased, significantly differing from group I (p<0.05). This allows us to recommend a low-mineralized silicon hydrocarbonate calcium-magnesium mineral water course for the prevention and treatment of side effects that occur at the beginning of statins and fibrates therapy. |
| Tags |
side effects, statins, fibrates, mineral water, stable angina |
| Bibliography |
- Kovalenko VM, Dorohoi AP. Sertsevo-sudynni khvoroby. Medychno-sotsialne znachennia ta stratehiya rozvytku kardiolohiyi v Ukrayini. Ukr. Kardiol. Zhurn [Internet]. 2016 Ber; 74(3): 5–14. Available from: http://journal.ukrcardio.org/kovalenko-1-3d-2016/. [in Ukrainian]
- Aslanabadi N, Habibi Asl B, Bakhshalizadeh B, Ghaderi F, Nemati M. Hypolipidemic activity of a natural mineral water rich in calcium, magnesium, and bicarbonate in hyperlipidemic adults. Adv Pharm Bull [Internet]. 2014; 4(3):303‒7. Available from: https://apb.tbzmed .ac.ir/Article/APB_117_20130720133451 DOI: 10.5681/apb.2014.044.
- Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA Cardiol [Internet]. 2017 Sep; 9(2):959‒66. Available from: https://jamanetwork. com/journals/jamacardiology/fullarticle/2646531 DOI:10.1001/ Jamacardio .2017.2289.
- Choi HD, Shin WG, Lee JY, Kang BC. Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis.Vascul Pharmacol [Internet]. 2015 Feb‒Mar; 6566:23‒30. Available from: https://www. sciencedirect.com/ science/article/pii/S1537189114001724?via%3Dihub DOI: 10.1016/j. vph.2014.11.002.
- Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, et. al. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol [Internet]. 2017 Oct 3; 70(14):1785‒822. Available from: https://www.sciencedirect.com/science/article/pii/S0735109717388988?via%3Dihub DOI: 10.1016/j. jacc.2017.07.745.
- Millan J, Pintó X, Brea A, Blasco M, Hernández-Mijares A, Ascaso J, et. al. Fibrates in the secondary prevention of cardiovascular disease (infarction and stroke). Results of a systematic review and meta-analysis of the Cochrane collaboration. Clin Investig Arterioscler [Internet]. 2018 Jan‒Feb; 30(1):30‒5. Available from: https://www.sciencedirect.com/science/article /abs/pii/ S02149 168173 01353?via%3Dihub DOI: 10.1016/j.arteri. 2017.11.001.
- Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol [Internet]. 2019 Feb; 39(2):e38‒e81. Available from: https://www. ahajournals.org/doi/pdf/10.1161/ATV.0000000000000073.
- Okopień B, Bułdak L, Bołdys A. Benefits and risks of the treatment with fibrates–a comprehensive summary. Expert Rev Clin Pharmacol [Internet]. 2018 Nov; 11(11):1099‒112. Available from: https://www.tandfonline.com/doi/abs/10.1080/ 17512433.2018.153778 0?journalCode =ierj20. DOI: 10.1080/17512433.2018.1537780.
- Quattrini S, Pampaloni B, Brandi ML. Natural mineral waters: chemical characteristics and health effects. Clin Cases Miner Bone Metab [Internet]. .2016 Sep‒Dec; 13(3):173‒80. Available from: https://www.ccmbm.com/ common/php/portiere.php?ID=9ce67591cf948dee1e9ffff195d3bcbd DOI: 10.11138/ccmbm/2016. 13.3.173.
- Townsend N, Nichols M, Scarborough P, Rayner M. Cardiovascular disease in Europe‒epidemiological update 2015. Eur Heart J [Internet]. 2015 Aug 25; 36:2696–705. Available from: https://academic.oup.com/eurheartj/ article/ 36/40/2696/ 2293417 DOI: 10.1093/eurheartj/ehv428.
- Toxqui L, Vaquero MP. An Intervention with Mineral Water Decreases Cardiometabolic Risk Biomarkers. A Crossover, Randomised, Controlled Trial with Two Mineral Waters in Moderately Hypercholesterolaemic Adults. Nutrients [Internet]. 2016 Jun 28; 8(7):400. Available from: https://www.mdpi.com/20726643/8/7/400 DOI: 10.3390/nu8070400.
- Zunnunov ZR The effectiveness of the application of medicinal mineral water from the 'Omonkhona' source in the patients presenting with the diseases of the hepatobiliary system. Vopr Kurortol Fizioter Lech Fiz Kult. [Internet]. 2019; 96(1):22‒29. DOI: 10.17116/kurort20199601122.
|
| Publication of the article |
«World of Medicine and Biology» №4(74), 2020 year, 53-58 pages, index UDK 615.272.4/327.06-08(043.3) |
| DOI |
10.26724/2079-8334-2020-4-74-53-58 |
